Single-dose oritavancin in the treatment of acute bacterial skin infections. - Wikidata - wikimedia - TriplyDB

Single-dose oritavancin in the treatment of acute bacterial skin infections.

Single-dose oritavancin in the treatment of acute bacterial skin infections.

http://www.wikidata.org/entity/Q40204783

about

New Is Old, and Old Is New: Recent Advances in Antibiotic-Based, Antibiotic-Free and Ethnomedical Treatments against Methicillin-Resistant Staphylococcus aureus Wound Infections Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections Dalbavancin for the treatment of acute bacterial skin and skin structure infections Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections New developments in the management of severe skin and deep skin structure infections - focus on tedizolid Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs.Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials.Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections.Vancomycin revisited - 60 years later Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens.Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Factors associated with decision to hospitalize emergency department patients with skin and soft tissue infection Oritavancin diphosphate The multifaceted role of commensal microbiota in homeostasis and gastrointestinal diseases.Library construction, selection and modification strategies to generate therapeutic peptide-based modulators of protein-protein interactions.Treatment outcome measures for randomized controlled trials of antibiotic treatment for acute bacterial skin and skin structure infections in the emergency department setting Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting Oritavancin for acute bacterial skin and skin structure infections.Vancomycin and the Risk of AKI: A Systematic Review and Meta-Analysis.Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis Microbiology and initial antibiotic therapy for injection drug users and non-injection drug users with cutaneous abscesses in the era of community-associated methicillin-resistant Staphylococcus aureus A Randomized Trial of Clindamycin Versus Trimethoprim-sulfamethoxazole for Uncomplicated Wound Infection Early Response in Cellulitis: A Prospective Study of Dynamics and Predictors.Current and emerging drugs for acute bacterial skin and skin structure infections: an update.Oritavancin: first global approval.Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections.Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review.Oritavancin: A Long-Half-Life Lipoglycopeptide.The times they are a-changin': new antibacterials for skin and skin structure infections.Vancomycin in the treatment of methicillin-resistant Staphylococcus aureus - a clinician's guide to the science informing current practice.Next-generation nanoantibacterial tools developed from peptides.Oritavancin: a review in acute bacterial skin and skin structure infections.Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.Interventions for the prevention of recurrent erysipelas and cellulitis.New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides.Oritavancin: a long-acting antibacterial lipoglycopeptide.Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options).

P2860

Q26749376-818BB52F-741A-47BD-AF71-91260EA13BB6 Q26772897-A9FA2949-C635-47D6-A6E9-61111DCB4D8B Q26799598-5602AA47-9B67-42A6-B779-411335BF6B8E Q26799701-BD5E3E74-655E-4A59-87B1-B48C6258E04F Q28083116-D83B906B-C527-4379-8647-0D4C525AA04A Q30251580-ABBB78BB-2893-4B54-9A15-576824385E91 Q30919516-AFA1A4E4-772A-4AFA-90E9-B18B6644A4D5 Q33437580-2254B3F4-3CCE-448A-ABBE-FD908B2E30FD Q33438834-E87461C7-9AD0-4660-86C8-A77A53CFC583 Q33732555-AD28A14E-D317-46DA-99CB-99CA6FF17E15 Q34433066-32C9D39A-3029-4604-812B-95922963EE8F Q34447679-E061E700-CD20-4F02-A2C6-66C30A1F6575 Q34478074-945F742A-3646-4A87-921D-1FD5DC173A0C Q35017990-323403F7-8163-4743-B3A0-86A5F688B6BC Q35057973-29AA216F-E0AD-41D8-A1D5-B2C24ADB3BAA Q35156014-9096EB8C-76B8-4CCD-8830-69CDAC1201F1 Q35532355-97DA08BA-AC91-4E19-9840-7DF75D496329 Q35656230-80FB03C8-1485-413A-8205-470A6C514BA9 Q36066564-371979E8-7C06-47DB-B8CE-EAFB35C18526 Q36086423-ED1F4ED7-432E-44F7-858F-83AB0CAFADB4 Q36206165-5FBCFA77-52B5-4D06-8417-E53B4BA5E810 Q36541737-121DD32A-382B-4331-BB2C-EBFEB188FEC1 Q36832857-AD8E7204-3788-4050-A894-2149D4E9B3E5 Q36948122-75257AE9-0DDD-4FD5-ABD9-926422FB7DA9 Q37284156-0425A3E3-6CFF-4F0A-9FD2-3CB0B7EF4014 Q38242081-0A0E9D67-A26E-4C97-B268-E2E2142E3824 Q38252710-3002C657-295E-4F72-8884-6BF67D3749BE Q38347765-8847F4CD-0F2F-4832-A36B-7959D3DA1911 Q38364691-F9086F4C-7D57-4E00-82B9-909E5519CF9E Q38434265-A94BEF84-875C-40D1-9C2C-F7A4E7D7195E Q38438503-DA90F9CF-C531-41F8-84A9-6BC193174E70 Q38462842-42A71B03-AE35-4563-BC17-7A958AE4177E Q38501669-AC83AD0B-3039-4398-B736-0085EFD889B2 Q38606618-3DF63BCC-BB43-4209-AC2B-70B97B732A28 Q38615330-3147328A-D99E-4C71-AB52-786D2121B4E8 Q38646905-C41653EC-C946-4101-B7EC-FA2DD515F0E4 Q38717950-23E2B87A-8FE7-418F-B925-2B696391F206 Q38768071-E8B74EF9-8975-4F57-BEB4-82C202F2C79C Q38830176-D2DBD50D-2FF5-4789-9986-3656C9F862DB Q38907793-1447CD34-CF4C-4D0D-A2E4-B4D9B33601B4

P2860

Single-dose oritavancin in the treatment of acute bacterial skin infections.

http://www.wikidata.org/entity/Q40204783

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Single-dose oritavancin in the treatment of acute bacterial skin infections.

@en

type

label

Single-dose oritavancin in the treatment of acute bacterial skin infections.

@en

prefLabel

Single-dose oritavancin in the treatment of acute bacterial skin infections.

@en

P1433

Q40204783-0480CD45-E165-4878-AF58-84ECC8EB5283

P1476

Q40204783-1B401084-D4C2-481D-8624-E5CA79797113

P2093

Q40204783-12FB10ED-1232-4718-9CE4-7DD3FC93C697

Q40204783-13169032-851F-4376-9345-BC4CBEE5F497

Q40204783-272C2A7F-4E57-4EC4-AFB8-E3FBAFE47271

Q40204783-333B2AB2-4B01-4576-B69E-4BA906C07FFC

Q40204783-510D40AD-00A5-4771-9474-5076158DF542

Q40204783-8D0B526D-DECD-4D4C-BFD6-CFC16C5F8D00

Q40204783-8EF1BF57-BE01-45A0-9065-15B6B7D8E3CF

Q40204783-A0D754E9-78E8-4B01-AE0B-56ADB04D0988

Q40204783-B04DE72B-E3BC-40D0-9C5D-7A5DE062427D

Q40204783-B13770FD-922B-4D1C-88A6-F977745B4556

P304

Q40204783-983B8F1B-9017-4C8A-A877-F9EC1E045D1A

P31

Q40204783-55A4C4F1-6E17-41D6-A44C-8DF9931461E9

P356

Q40204783-529FDFBD-48AF-450E-B7D4-18393D63CBEF

P407

Q40204783-8A212F86-7B89-4155-9DBD-170FACF8B9C0

P433

Q40204783-CA654C80-9DD6-4D31-8366-744C221033C3

P478

Q40204783-AC28B0F7-AEB4-49B2-880C-B60202DB7EE4

P50

Q40204783-6075F86B-E2A6-4AAB-BB6A-B66B2FC0BB1D

P577

Q40204783-B703C89D-20F1-4CA3-A5E1-ECA963C0A07E

P698

Q40204783-76DCB963-02C2-42D4-98D2-C0E034F90C5D

P921

Q40204783-9676ACE3-8065-46BF-85E5-F0155806C185

P356

P1433

The New England Journal of Medicine

P1476

Single-dose oritavancin in the treatment of acute bacterial skin infections

@en

P2093

Antonio Perez

http://www.w3.org/2001/XMLSchema#string

Ashwin Porwal

http://www.w3.org/2001/XMLSchema#string

Christopher Lucasti

http://www.w3.org/2001/XMLSchema#string

G Ralph Corey

http://www.w3.org/2001/XMLSchema#string

Hai Jiang

http://www.w3.org/2001/XMLSchema#string

Heidi Kabler

http://www.w3.org/2001/XMLSchema#string

J Scott Overcash

http://www.w3.org/2001/XMLSchema#string

Philip Giordano

http://www.w3.org/2001/XMLSchema#string

Purvi Mehra

http://www.w3.org/2001/XMLSchema#string

SOLO I Investigators

http://www.w3.org/2001/XMLSchema#string

P304

2180-2190

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1310422

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

370

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24897083

http://www.w3.org/2001/XMLSchema#string

P921